Pre-made Brodalumab benchmark antibody ( Whole mAb, anti-IL17RA/IL17R therapeutic antibody, Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-082

Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-082-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody
INN Name Brodalumab
TargetIL17R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAmgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma
Conditions ApprovedErythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis
Conditions ActiveAxial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis
Conditions DiscontinuedAsthma;Crohn's disease;Rheumatoid arthritis
Development TechAbgenix XenoMouse